A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

PURPOSE: CB-103 selectively inhibits the CSL–NICD (Notch intracellular domain) interaction leading to transcriptional downregulation of oncogenic Notch pathway activation. This dose-escalation/expansion study aimed to determine safety, pharmacokinetics, and preliminary antitumor activity. EXPERIMENT...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Glenn J., Stathis, Anastasios, Lopez-Miranda, Elena, Racca, Fabricio, Quon, Doris, Leyvraz, Serge, Hess, Dagmar, Keam, Bhumsuk, Rodon, Jordi, Ahn, Myung-Ju, Kim, Hye Ryun, Schneeweiss, Andreas, Ribera, Josep-Maria, DeAngelo, Daniel, Perez Garcia, Jose Manuel, Cortes, Javier, Schönborn-Kellenberger, Oliver, Weber, Dirk, Pisa, Pavel, Bauer, Michael, Beni, Laura, Bobadilla, Maria, Lehal, Raj, Vigolo, Michele, Vogl, Florian D., Garralda, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501326/
https://www.ncbi.nlm.nih.gov/pubmed/37712875
http://dx.doi.org/10.1158/2767-9764.CRC-23-0333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501326/
https://www.ncbi.nlm.nih.gov/pubmed/37712875
http://dx.doi.org/10.1158/2767-9764.CRC-23-0333

Ejemplares similares